Immuron Update on IMM-124E SARS-CoV-2 Research
August 19 2022 - 6:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and
clinical-stage biopharmaceutical company with a proprietary
technology platform for prevention and treatment of gut-mediated
diseases; today announced that it has deprioritized SARS-CoV-2
research to focus on the clinical development of our more advanced
stage therapeutic drug candidates.
Immuron enters FY23 with a newly appointed CEO
who is completing an assessment of the entire product portfolio,
target markets, competitive advantage, and key growth drivers.
In consideration of our research findings, the
rapid evolution of the virus and changing treatment landscape
presents significant challenges to conduct a clinical trial for
SARS-CoV-2 with IMM-124E.
Immuron has previously reported IMM-124E
research investigations demonstrating neutralizing activity against
SARS-CoV-2 (ASX announcements dated 13 May 2021, 15 December 2020,
and 21 July 2020). The company has been pursuing the antiviral
activities of IMM-124E, focusing on establishing a better
understanding of the mechanism of action associated with these
initial observations. CSIRO conducted Quantitative Mass
Spectrometry analysis (LC-MS/MS) to identify potential antiviral
agents that are significantly enriched in IMM-124E. Quantitative
proteomics identified at least 53 proteins that are significantly
overexpressed in IMM-124E compared to the Milk Powder control
samples. This included 17 immunoglobulin-like proteins that appear
to be enriched between two- to nine-fold in Immuron Colostrum drug
substance and several small antimicrobial proteins known to
function in defense against bacterial infections.
Immuron has dedicated significant resources to
interrogate the mechanism of SARS-CoV-2 protection, however, the
mechanism of how IMM-124E provides protection against SARS-CoV-2
viral infection remains unclear.
This release has been authorised by the
directors of Immuron Limited.
COMPANY
CONTACT:Steven
LydeamoreChief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
|
|
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024